NCT05383196 - Onvansertib + Paclitaxel In TNBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

February 15, 2026

Study Completion Date

February 15, 2029

Conditions

Breast CancerInvasive Breast CancerUnresectable Breast CarcinomaLocally Advanced Breast CancerMetastatic Breast CancerInflammatory Breast CancerTriple Negative Breast Cancer (TNBC)Hormone Receptor/Growth Factor Receptor-Negative Breast CancerHER2-negative Breast CancerHormone Receptor Negative Breast Carcinoma

Interventions

DRUG

Onvansertib

oral administration, once daily for 21 consecutive days, followed by 7 days without drug, to complete a cycle of 28 days.

DRUG

Paclitaxel

once a week into your vein (by intravenous infusion) over about 30 minutes. This will continue for 3 weeks of every cycle

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconness Medical Center, Boston

Dana-Farber Cancer Institute, Boston